{"product_id":"comparing-seven-antibody-drug-conjugates-for-previously-treated-her2-positive-advanced-breast-cancer-what-a-major-network-analysis-found","title":"Comparing Seven Antibody-Drug Conjugates for Previously Treated HER2-Positive Advanced Breast Cancer: What a Major Network Analysis Found","description":"\u003cp\u003eThis network meta-analysis pooled seven phase III randomized trials covering 3,160 patients. The analysis compared seven antibody-drug conjugates (ADCs) in HER2-positive advanced breast cancer that had progressed after trastuzumab or taxane treatment. All seven ADCs improved progression-free survival compared with chemotherapy plus a tyrosine kinase inhibitor. Trastuzumab deruxtecan (T-DXd) gave the largest progression-free survival benefit (hazard ratio 0.18, 95% CI 0.13–0.25), and SHR-A1811 showed the strongest overall survival signal (hazard ratio 0.31, 95% CI 0.14–0.69). Safety differed between drugs: T-DXd had the highest odds of any-grade treatment-related side effects, while T-DM1 had the lowest odds of severe (grade 3 or higher) side effects.\u003c\/p\u003e\n\n\u003ch1\u003eComparing Seven Antibody-Drug Conjugates for Previously Treated HER2-Positive Advanced Breast Cancer: What a Major Network Analysis Found\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#what-are-adcs\"\u003eWhat Are Antibody-Drug Conjugates?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Researchers Conducted the Study\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#studies-included\"\u003eThe Seven Trials and 3,160 Patients Included\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#quality\"\u003eHow Reliable Were the Included Trials?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#pfs\"\u003eKey Finding 1: Progression-Free Survival Results\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#os\"\u003eKey Finding 2: Overall Survival Results\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#subgroups\"\u003eKey Finding 3: Results in Specific Patient Groups\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#safety\"\u003eKey Finding 4: Safety and Side Effects\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#implications\"\u003eWhat These Findings Mean for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003ePractical Points for Patients and Families\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a network meta-analysis of seven phase III trials covering 3,160 patients, all seven antibody-drug conjugates significantly improved progression-free survival versus chemotherapy plus a tyrosine kinase inhibitor.\u003c\/li\u003e\n\u003cli\u003eT-DXd showed the largest progression-free survival benefit (hazard ratio 0.18, 95% CI 0.13–0.25); SHR-A1811 showed the strongest overall survival signal (hazard ratio 0.31, 95% CI 0.14–0.69).\u003c\/li\u003e\n\u003cli\u003eT-DXd had the highest odds of any-grade treatment-related side effects, while T-DM1 had the lowest odds of severe (grade 3 or higher) side effects.\u003c\/li\u003e\n\u003cli\u003eOverall survival data were immature for several trials, so the authors describe the survival ranking as a hypothetical exploration rather than a definitive conclusion.\u003c\/li\u003e\n\u003cli\u003eComparisons between individual conjugates are indirect, each supported by only one study, and treatment choices should be made with the treating oncology team.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\u003cp\u003eOver the past decade, antibody-drug conjugates (ADCs) have completely changed the treatment landscape for advanced HER2-positive breast cancer. HER2-positive means the cancer cells carry large amounts of a protein called HER2 on their surface, which drives the cancer to grow.\u003c\/p\u003e\n\n\u003cp\u003eTrastuzumab emtansine (T-DM1) was the first ADC approved for HER2-positive metastatic breast cancer. T-DM1 became a standard second-line option after trastuzumab treatment stopped working. The DESTINY-Breast01 study then showed that trastuzumab deruxtecan (T-DXd) worked remarkably well in later lines of treatment. The DESTINY-Breast02 trial confirmed that T-DXd was superior to the physician's choice of therapy in patients who had received at least one prior anti-HER2 regimen. That result supported approval of T-DXd for later-line use.\u003c\/p\u003e\n\n\u003cp\u003eA confirmatory phase III study within the DESTINY program then showed that T-DXd significantly outperformed T-DM1 on both progression-free survival (PFS, the time before the cancer grows again) and overall survival (OS, the time until death from any cause). That study enrolled patients who had prior trastuzumab and taxane exposure. It provided the evidence basis for global second-line approval of T-DXd.\u003c\/p\u003e\n\n\u003cp\u003eMeanwhile, newer ADCs developed in China have also shown good results in phase III trials. These drugs include disitamab vedotin (RC48), SHR-A1811, ARX788, and DP303c.\u003c\/p\u003e\n\n\u003cp\u003eHowever, no adequate head-to-head randomized controlled trials (RCTs) have directly compared these different ADCs against each other. For patients whose cancer has progressed after trastuzumab or taxane, doctors still face uncertainty about how to choose an ADC scientifically. Safety also differs substantially between ADCs. The adverse events linked to these therapies may directly compromise the health-related quality of life of treated patients.\u003c\/p\u003e\n\n\u003cp\u003eThis study aimed to conduct a systematic review and network meta-analysis (NMA). A network meta-analysis is a statistical method that compares several treatments indirectly, even when they have never been tested head-to-head. The goal was to clarify the efficacy and safety ranking of different ADCs for HER2-positive advanced breast cancer after failure of trastuzumab or taxane-based treatment. The authors hope this ranking will help patients obtain a better treatment experience.\u003c\/p\u003e\n\n\u003ch2 id=\"what-are-adcs\"\u003eWhat Are Antibody-Drug Conjugates?\u003c\/h2\u003e\n\u003cp\u003eAn antibody-drug conjugate is a single medicine built from two parts joined together. The first part is an antibody, a protein that recognizes and attaches to a specific target on cancer cells. In these drugs, the antibody targets HER2. The second part is a powerful chemotherapy payload attached to the antibody.\u003c\/p\u003e\n\n\u003cp\u003eThis design delivers the chemotherapy directly to cancer cells that carry HER2. The approach aims to concentrate the anti-cancer effect on the tumor while limiting exposure of healthy tissue. Different ADCs use different antibodies, different payloads, and different chemical linkers, so their effectiveness and side-effect profiles differ.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Researchers Conducted the Study\u003c\/h2\u003e\n\u003cp\u003eThe researchers registered their plan in PROSPERO before starting the analysis. PROSPERO is a public registry of systematic reviews. The registration number was CRD420251234345. The team followed the PRISMA guidelines, which are the standard reporting rules for systematic reviews and meta-analyses.\u003c\/p\u003e\n\n\u003cp\u003eThe team performed a comprehensive literature search across three major academic databases: PubMed, Embase, and the Cochrane Library. The search covered all records from the establishment of each database to 31 December 2025. The researchers also manually searched conference abstracts from the American Society of Clinical Oncology, the European Society for Medical Oncology, and the San Antonio Breast Cancer Symposium annual meetings. The manual search covered abstracts published from June 2020 to December 2025.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers verified all included abstracts and included only English-language literature. A PRISMA flow chart documented the screening process.\u003c\/p\u003e\n\n\u003cp\u003eThe inclusion criteria for clinical trials were as follows:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003ePhase III randomized controlled trials.\u003c\/li\u003e\n\u003cli\u003ePatients diagnosed with HER2-positive advanced breast cancer who had been previously treated with trastuzumab or had received systemic therapy built on a taxane backbone.\u003c\/li\u003e\n\u003cli\u003eAt least one HER2-targeted ADC included in the trial group or the control group.\u003c\/li\u003e\n\u003cli\u003eDetailed results and toxic effects reported, including PFS, grade 3 or higher treatment-related adverse events (TRAEs), and OS when available.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eStudies lacking OS data, or studies where such data could not be obtained, could still be included. For those studies, the analysis evaluated recurrence-free survival time and safety instead. Studies that did not meet the above criteria were excluded.\u003c\/p\u003e\n\n\u003cp\u003eTwo researchers (F.L. and G.Y.) independently retrieved and screened the trials based on the inclusion and exclusion criteria. If multiple studies reported the same research, the latest data was taken as the standard. A third researcher (Y.P.) resolved any disputes.\u003c\/p\u003e\n\n\u003cp\u003eThe team systematically extracted key data and recorded it in Microsoft Excel. The extracted data included the first author, publication year, study title, NCT number, sample size, intervention and control measures, number of previous anti-tumor treatment lines, primary efficacy endpoints, and TRAEs. The two researchers (F.L. and G.Y.) conducted the extraction independently, and the third researcher (Y.P.) resolved any differences. If necessary, the team would consider contacting the authors to obtain data. If the data could not be obtained, the study would be excluded.\u003c\/p\u003e\n\n\u003cp\u003eTwo independent reviewers (J.L. and X.H.) used the Cochrane Risk of Bias Assessment Tool Version 2.0 (RoB 2) to appraise the risk of bias in the randomized controlled trials. A third reviewer (Y.P.) resolved disagreements.\u003c\/p\u003e\n\n\u003cp\u003eFor the statistical analysis, the researchers performed a network meta-analysis within the frequentist statistical framework. They adopted a random-effects model to estimate effect sizes, reported as hazard ratios (HR) or odds ratios (OR), with corresponding 95% confidence intervals (CI).\u003c\/p\u003e\n\n\u003cp\u003eChemotherapy plus a tyrosine kinase inhibitor (Chem + TKI) was prespecified as the reference treatment for all comparisons. A tyrosine kinase inhibitor is a drug that blocks growth signals inside cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers assessed transitivity assumptions by comparing the distribution of key potential effect modifiers across the included studies. These modifiers included the number of previous lines of therapy, hormone receptor status, and the control regimen.\u003c\/p\u003e\n\n\u003cp\u003eThe proportion of patients who had received two or more prior lines of therapy ranged from 11.30% to 59.70% across the included trials. All trials included patients with HER2-positive advanced breast cancer who had received previous treatment with trastuzumab or a taxane. All included trials reported data on subgroups by hormone-receptor status, and the adjudication criteria were consistent. The researchers further conducted subgroup analyses based on this variable. Control regimens were generally homogeneous, mainly Chem + TKI or T-DM1. Based on this assessment, the indirect comparison in this network meta-analysis basically satisfies the transitivity assumption.\u003c\/p\u003e\n\n\u003cp\u003eFor survival outcomes, an HR below 1 indicated that the experimental group performed better than the reference treatment. For safety outcomes, an OR below 1 suggested a lower odds of adverse events in the experimental group, meaning greater safety.\u003c\/p\u003e\n\n\u003cp\u003eIn the evidence network of this study, each direct comparison was supported by only one independent single study. There was no closed loop among the various treatment measures. Therefore, the researchers could not effectively estimate the heterogeneity parameters (I² and τ²) using conventional methods. They also could not use the node-splitting method to formally evaluate consistency between direct and indirect evidence.\u003c\/p\u003e\n\n\u003cp\u003eTo partially overcome this methodological limitation, the researchers prespecified the use of a random-effects model. Because data from only individual studies contributed to each direct comparison, the team estimated the between-study variance (τ²) on the basis of the entire evidence network. They used the DerSimonian-Laird method, which is implemented by default in R packages.\u003c\/p\u003e\n\n\u003cp\u003eTo further test the robustness of the results, the researchers conducted a \"leave-one-out\" sensitivity analysis. This analysis assessed the impact of eliminating each individual trial on the pooled effect size and treatment ranking. The team also conducted subgroup analyses for the HR-negative\/HER2-positive population and the visceral metastasis population to verify the reliability of the main analysis results. Visceral metastasis means the cancer has spread to internal organs. All analyses were performed using the R software package \"netmeta.\"\u003c\/p\u003e\n\n\u003cp\u003eThe researchers presented the direct comparison relationships among intervention measures through a network diagram. The size of the nodes represents the total sample size of each intervention group. The thickness of the lines represents the number of studies for the direct comparisons.\u003c\/p\u003e\n\n\u003cp\u003eThe team used the P-score to sort all included intervention measures. The P-score is a frequentist ranking indicator for network meta-analysis. A greater P-score value denoted both more favorable therapeutic efficacy and a lower risk of treatment-related adverse events. The HR\/OR and 95% CI matrix for all pairwise comparisons of treatments was generated through a league table.\u003c\/p\u003e\n\n\u003ch2 id=\"studies-included\"\u003eThe Seven Trials and 3,160 Patients Included\u003c\/h2\u003e\n\u003cp\u003eThe analysis included a total of seven phase III randomized controlled trials involving 3,160 patients. These trials covered 8 treatment groups and 7 targeted HER2 ADCs: T-DM1, ARX788, A166, SHR-A1811, RC48, DP303c, and T-DXd.\u003c\/p\u003e\n\n\u003cp\u003eAll studies were randomized controlled phase III clinical trials for HER2-positive advanced breast cancer that had failed previous treatment with trastuzumab or a taxane. The RC48-C006 study enrolled only patients with liver metastasis from HER2-positive advanced breast cancer. Therefore, that study was included only in the visceral metastasis subgroup analysis.\u003c\/p\u003e\n\n\u003cp\u003eThe PFS network meta-analysis for all populations included six other studies and excluded the RC48-C006 study. Because the DP303c study was missing OS data, the OS network meta-analysis for the entire population included five other studies. The OS network meta-analysis excluded both the RC48-C006 and DP303c studies.\u003c\/p\u003e\n\n\u003cp\u003eThe individual trials and their key results were as follows:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eEMILIA (Diéras et al., 2017):\u003c\/strong\u003e T-DM1 (495 patients) versus Chem + TKI (496 patients). Median PFS was 9.60 versus 6.40 months (HR 0.65, 95% CI 0.55–0.77). Median OS was 29.9 versus 25.9 months (HR 0.75, 95% CI 0.64–0.88). In this trial, 39.00% of patients had received two or more prior treatment lines. Follow-up time was 19.10 versus 18.60 months.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eE-breast-02 (Hu et al., 2025a):\u003c\/strong\u003e ARX788 (221 patients) versus Chem + TKI (220 patients). Median PFS was 11.30 versus 8.20 months (HR 0.64, 95% CI 0.49–0.82). OS was not reported (NR) in either group (HR 0.71, 95% CI 0.46–1.10). In this trial, 33.50% of patients had received two or more prior treatment lines. Follow-up time was 11.10 months.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKL166-III-06 (Hu et al., 2025b):\u003c\/strong\u003e A166 (182 patients) versus T-DM1 (183 patients). Median PFS was 11.10 versus 4.40 months (HR 0.39, 95% CI 0.30–0.51). OS was not reported in either group (HR 0.62, 95% CI 0.38–1.03). In this trial, 53.80% of patients had received two or more prior treatment lines. Follow-up time was 14.90 months.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHORIZON-Breast01 (Song et al., 2025):\u003c\/strong\u003e SHR-A1811 (142 patients) versus Chem + TKI (145 patients). Median PFS was 30.60 versus 8.30 months (HR 0.22, 95% CI 0.15–0.34). OS was not reported in either group (HR 0.31, 95% CI 0.14–0.69). In this trial, 16.20% of patients had received two or more prior treatment lines. Follow-up time was 15.90 versus 15.30 months.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDESTINY-Breast03 (Cortés et al., 2024):\u003c\/strong\u003e T-DXd (261 patients) versus T-DM1 (263 patients). Median PFS was not reached versus 6.80 months (HR 0.28, 95% CI 0.22–0.37). OS was not reported in either group (HR 0.55, 95% CI 0.36–0.86). In this trial, 49.40% of patients had received two or more prior treatment lines. Follow-up time was 16.20 versus 15.30 months.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRC48-C006 (Wang et al., 2025):\u003c\/strong\u003e RC48 (53 patients) versus Chem + TKI (51 patients). Median PFS was not reported in either group (HR 0.56, 95% CI 0.350–0.90). OS was not reported in either group (HR 0.56, 95% CI 0.35–0.90). In this trial, 11.30% of patients had received two or more prior treatment lines. Follow-up time was 15.38 versus 19.35 months. This study exclusively enrolled HER2-positive advanced breast cancer with liver metastasis. Therefore, the corresponding data were incorporated solely into the visceral metastasis subgroup analysis and excluded from the overall population analysis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNCT06313086 (Hu et al., 2026):\u003c\/strong\u003e DP303c (226 patients) versus T-DM1 (222 patients). Median PFS was 8.80 versus 5.80 months (HR 0.56, 95% CI 0.42–0.75). OS was not reported. In this trial, 59.70% of patients had received two or more prior treatment lines. Follow-up time was 7.40 months.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"quality\"\u003eHow Reliable Were the Included Trials?\u003c\/h2\u003e\n\u003cp\u003eThe researchers applied the Cochrane RoB 2 tool to assess the risk of bias of the included randomized controlled trials. Four studies (A166, RC48, SHR-A1811, DP303c) had incomplete reporting of randomization details. These four studies therefore raised some concerns for the randomization process domain. The remaining three trials were rated low risk in this domain.\u003c\/p\u003e\n\n\u003cp\u003eAll seven trials had an open-label design, meaning patients and doctors knew which treatment was given. The reviewers identified no deviations from the intended interventions associated with knowledge of treatment allocation. Appropriate intention-to-treat (ITT) analyses were performed. Intention-to-treat means all patients were analyzed in the group to which they were assigned. Therefore, the domain of deviations from intended interventions was judged as low risk across all studies.\u003c\/p\u003e\n\n\u003cp\u003eThe primary endpoint was adjudicated by a blinded independent central review (BICR), with reviewers masked to treatment assignment. Accordingly, the domain of measurement of the outcome was rated low risk for all trials.\u003c\/p\u003e\n\n\u003cp\u003eFor the domain of missing outcome data, the three fully published trials were rated low risk. These trials provided full reporting of censoring and missing data. For the four trials available only as conference abstracts (A166, RC48, SHR-A1811, DP303c), exact counts and reasons for missing outcome data were not reported. This precluded independent verification of the completeness of outcome data, so these four studies were assigned some concerns.\u003c\/p\u003e\n\n\u003cp\u003eFor the domain of selection of the reported result, studies without publicly available statistical analysis plans (SAPs) raised some concerns. Most of these were conference abstracts. Trials with accessible full protocols or SAPs were rated low risk.\u003c\/p\u003e\n\n\u003cp\u003eOverall, the included studies were judged to have either low risk or some concerns. No trial was rated high risk in any domain. The concerns mainly stemmed from incomplete descriptions of randomization, unavailable public SAPs, and limited reporting of missing outcome data for several conference-abstract trials.\u003c\/p\u003e\n\n\u003ch2 id=\"pfs\"\u003eKey Finding 1: Progression-Free Survival Results\u003c\/h2\u003e\n\u003cp\u003eEvery ADC in the analysis lengthened the time before cancer progressed compared with chemotherapy plus a tyrosine kinase inhibitor. This benefit was statistically significant for all seven drugs.\u003c\/p\u003e\n\n\u003cp\u003eThe PFS analysis of the overall population included seven intervention measures: Chem + TKI, A166, ARX788, DP303c, SHR-A1811, T-DM1, and T-DXd. These measures covered six direct comparisons. The network diagram showed multiple direct comparisons among the intervention measures. No closed loops existed in the network, meaning all comparisons were either direct or indirect, without a combination of both for any treatment pair.\u003c\/p\u003e\n\n\u003cp\u003eCompared with the reference treatment, all treatment groups showed a PFS advantage (HR below 1), and this difference reached statistical significance. The size of the benefit differed substantially between drugs:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eT-DXd\u003c\/strong\u003e had the most favorable PFS benefit (HR 0.18, 95% CI 0.13–0.25).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSHR-A1811\u003c\/strong\u003e ranked second (HR 0.22, 95% CI 0.15–0.33).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eA166\u003c\/strong\u003e followed (HR 0.25, 95% CI 0.19–0.35).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDP303c\u003c\/strong\u003e showed an HR of 0.36 (95% CI 0.26–0.51).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eARX788\u003c\/strong\u003e showed an HR of 0.64 (95% CI 0.49–0.83).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eT-DM1\u003c\/strong\u003e showed an HR of 0.65 (95% CI 0.55–0.77).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe P-score ranking confirmed the order of PFS advantages among the treatment groups: T-DXd (0.95) came first, followed by SHR-A1811 (0.82), A166 (0.72), DP303c (0.51), ARX788 (0.26), T-DM1 (0.24), and Chem + TKI (0.00).\u003c\/p\u003e\n\n\u003cp\u003eThe league table also allowed direct pairwise comparisons between individual ADCs. For example, T-DXd was compared with T-DM1 (HR 0.28, 95% CI 0.22–0.36) and with ARX788 (HR 0.28, 95% CI 0.19–0.43). SHR-A1811 was compared with T-DM1 (HR 0.34, 95% CI 0.22–0.53) and with ARX788 (HR 0.34, 95% CI 0.21–0.56). A166 was compared with T-DM1 (HR 0.39, 95% CI 0.30–0.51) and with ARX788 (HR 0.40, 95% CI 0.26–0.59). DP303c was compared with T-DM1 (HR 0.56, 95% CI 0.42–0.75) and with ARX788 (HR 0.57, 95% CI 0.37–0.87).\u003c\/p\u003e\n\n\u003cp\u003eSome comparisons did not reach statistical significance. T-DXd versus SHR-A1811 gave an HR of 0.83 (95% CI 0.50–1.38). T-DXd versus A166 gave an HR of 0.72 (95% CI 0.50–1.04). SHR-A1811 versus A166 gave an HR of 0.87 (95% CI 0.52–1.45). A166 versus DP303c gave an HR of 0.70 (95% CI 0.47–1.03). ARX788 versus T-DM1 gave an HR of 0.98 (95% CI 0.72–1.34).\u003c\/p\u003e\n\n\u003ch2 id=\"os\"\u003eKey Finding 2: Overall Survival Results\u003c\/h2\u003e\n\u003cp\u003eAll the antibody-drug conjugates in the overall survival analysis except ARX788, including SHR-A1811 and T-DXd, showed a statistically significant overall survival advantage over chemotherapy plus a tyrosine kinase inhibitor. ARX788 was the only antibody-drug conjugate that did not reach statistical significance for overall survival in this analysis.\u003c\/p\u003e\n\n\u003cp\u003eThe OS analysis for the overall population included six intervention measures: Chem + TKI, A166, ARX788, SHR-A1811, T-DM1, and T-DXd. These measures covered five direct comparisons.\u003c\/p\u003e\n\n\u003cp\u003eAll treatment groups except ARX788 demonstrated an OS advantage (HR below 1) with a statistically significant difference compared with the reference treatment. The results were as follows:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSHR-A1811\u003c\/strong\u003e showed the most prominent OS benefit (HR 0.31, 95% CI 0.14–0.69).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eT-DXd\u003c\/strong\u003e ranked second (HR 0.41, 95% CI 0.26–0.66).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eA166\u003c\/strong\u003e showed an HR of 0.47 (95% CI 0.28–0.78).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eT-DM1\u003c\/strong\u003e showed an HR of 0.75 (95% CI 0.64–0.88).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eARX788\u003c\/strong\u003e showed an HR of 0.71 (95% CI 0.46–1.10), which did not reach statistical significance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe P-score ranking results were consistent with the league table data. SHR-A1811 was the most likely to have the best OS advantage (P-score 0.89), followed by T-DXd (P-score 0.77) among the included ADCs.\u003c\/p\u003e\n\n\u003cp\u003eThe authors added an important caution. Overall survival data from multiple clinical trials, such as HORIZON-Breast01 and KL166-III-06, were not yet mature. Therefore, the observed OS ranking is a hypothetical exploration result rather than a definitive conclusion.\u003c\/p\u003e\n\n\u003ch2 id=\"subgroups\"\u003eKey Finding 3: Results in Specific Patient Groups\u003c\/h2\u003e\n\u003cp\u003eThe researchers also analyzed PFS in two specific groups: patients with hormone receptor-negative, HER2-positive cancer (HR-negative\/HER2-positive), and patients with visceral metastasis.\u003c\/p\u003e\n\n\u003cp\u003eFor the HR-negative\/HER2-positive population, five intervention measures were included: Chem + TKI, ARX788, SHR-A1811, T-DM1, and T-DXd. These measures covered four direct comparisons. Compared with the reference treatment, all treatment groups showed a PFS advantage (HR below 1) with a statistically significant difference. T-DXd had the most significant PFS advantage (HR 0.17, 95% CI 0.11–0.27), followed by SHR-A1811 (HR 0.23, 95% CI 0.13–0.42). These results were consistent with the results from the entire population. The P-score results were consistent with the league table results.\u003c\/p\u003e\n\n\u003cp\u003eFor the visceral metastasis population, six intervention measures were included: Chem + TKI, ARX788, SHR-A1811, T-DM1, T-DXd, and RC48. These measures covered five direct comparisons. The league table and the P-score results also indicated that the ADCs performed favorably in this group.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eKey Finding 4: Safety and Side Effects\u003c\/h2\u003e\n\u003cp\u003eSafety differed markedly between the ADCs. T-DXd had the highest odds of any-grade treatment-related side effects, while T-DM1 had the lowest odds of severe (grade 3 or higher) side effects.\u003c\/p\u003e\n\n\u003cp\u003eSix intervention measures (Chem + TKI, A166, ARX788, SHR-A1811, T-DM1, T-DXd, RC48) were included for seven direct comparisons to analyze all-grade TRAEs and grade 3 or higher TRAEs. Grade 3 or higher means the side effect is severe or potentially life-threatening.\u003c\/p\u003e\n\n\u003cp\u003eFor all-grade treatment-related adverse events, T-DXd exhibited the highest odds relative to all included control treatments. Statistically significant differences were identified when T-DXd was compared with T-DM1 and with Chem + TKI. Specifically, the odds of all-grade TRAEs with T-DXd were 7.86 times higher than with T-DM1 (OR 7.86, 95% CI 3.03–20.40). The odds were 4.23 times higher than with Chem + TKI (OR 4.23, 95% CI 1.26–14.22). Both differences reached statistical significance.\u003c\/p\u003e\n\n\u003cp\u003eFor grade 3 or higher TRAEs, T-DM1 demonstrated better safety characteristics. T-DM1 had a significantly lower odds of occurrence than several other treatments:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompared with SHR-A1811: OR 0.44 (95% CI 0.25–0.76)\u003c\/li\u003e\n\u003cli\u003eCompared with ARX788: OR 0.58 (95% CI 0.37–0.92)\u003c\/li\u003e\n\u003cli\u003eCompared with DP303c: OR 0.44 (95% CI 0.30–0.65)\u003c\/li\u003e\n\u003cli\u003eCompared with Chem + TKI: OR 0.61 (95% CI 0.48–0.79)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat These Findings Mean for Patients\u003c\/h2\u003e\n\u003cp\u003eThis analysis supports the use of anti-HER2 ADCs over chemotherapy plus a tyrosine kinase inhibitor in patients whose HER2-positive advanced breast cancer has progressed after trastuzumab or taxane. All seven ADCs significantly improved progression-free survival compared with the reference treatment.\u003c\/p\u003e\n\n\u003cp\u003eAmong the seven drugs, T-DXd and SHR-A1811 delivered notable survival benefits. T-DXd produced the largest reduction in the risk of cancer progression. SHR-A1811 produced the largest reduction in the risk of death in this indirect analysis.\u003c\/p\u003e\n\n\u003cp\u003eThe results also show that efficacy and safety do not always move together. T-DXd was associated with a higher odds of all-grade treatment-related side effects. T-DM1 exhibited favorable safety for grade 3 or higher side effects. This trade-off matters for patients, because side effects can directly affect quality of life during treatment.\u003c\/p\u003e\n\n\u003cp\u003eFor doctors, these rankings offer a structured way to think about treatment selection when no head-to-head trials exist. For patients, the findings suggest that the choice of ADC may reasonably depend on the balance between expected benefit and tolerance of side effects.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Study Could Not Prove\u003c\/h2\u003e\n\u003cp\u003eThis is a network meta-analysis, not a head-to-head trial. The comparisons between individual ADCs are indirect, meaning they are inferred through a common reference treatment rather than tested directly in the same patients.\u003c\/p\u003e\n\n\u003cp\u003eEach direct comparison in the evidence network was supported by only one independent single study. There was no closed loop among the treatment measures. As a result, the researchers could not effectively estimate heterogeneity parameters using conventional methods. They also could not formally evaluate consistency between direct and indirect evidence using the node-splitting method.\u003c\/p\u003e\n\n\u003cp\u003eSeveral trials were available only as conference abstracts. For these trials (A166, RC48, SHR-A1811, DP303c), exact counts and reasons for missing outcome data were not reported. This limited independent verification of the completeness of outcome data.\u003c\/p\u003e\n\n\u003cp\u003eOverall survival data were immature for multiple trials, including HORIZON-Breast01 and KL166-III-06. The authors therefore describe the OS ranking as a hypothetical exploration result rather than a definitive conclusion.\u003c\/p\u003e\n\n\u003cp\u003eThe RC48-C006 study enrolled only patients with liver metastasis. Its data were therefore used only in the visceral metastasis subgroup analysis and excluded from the overall population analysis. The DP303c study lacked OS data, so it was excluded from the OS analysis.\u003c\/p\u003e\n\n\u003cp\u003eThe proportion of patients who had received two or more prior lines of therapy varied widely across trials, from 11.30% to 59.70%. This variation could influence the comparisons, although the researchers assessed the transitivity assumption as basically satisfied.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003ePractical Points for Patients and Families\u003c\/h2\u003e\n\u003cp\u003eThese findings come from a statistical comparison of trials, not from a new clinical trial. Treatment decisions should always be made with the treating oncology team, who consider each patient's prior treatments, hormone receptor status, organ function, and side-effect tolerance.\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003eAsk your doctor which antibody-drug conjugates are approved and available for your specific situation after trastuzumab or taxane treatment.\u003c\/li\u003e\n\u003cli\u003eDiscuss both expected benefit and side-effect profile for each option. In this analysis, T-DXd gave the largest progression-free survival benefit but had the highest odds of any-grade side effects.\u003c\/li\u003e\n\u003cli\u003eAsk about severe side effects specifically. In this analysis, T-DM1 had the lowest odds of grade 3 or higher treatment-related side effects.\u003c\/li\u003e\n\u003cli\u003eAsk whether your cancer is hormone receptor-negative or has spread to internal organs. The researchers analyzed these groups separately, and the ADC benefits remained consistent.\u003c\/li\u003e\n\u003cli\u003eRecognize that overall survival rankings are still uncertain, because survival data from several trials were not yet mature.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is an antibody-drug conjugate?\u003c\/h3\u003e\n\u003cp\u003eAn antibody-drug conjugate is one medicine made of two joined parts: an antibody that attaches to a target on cancer cells, and a powerful chemotherapy payload. In these drugs the antibody targets HER2, aiming to deliver chemotherapy to cancer cells while limiting exposure of healthy tissue. Different conjugates use different antibodies, payloads and linkers, so their effects and side effects differ.\u003c\/p\u003e\n\u003ch3\u003eWho was included in this network meta-analysis?\u003c\/h3\u003e\n\u003cp\u003eIt pooled seven phase III randomized trials covering 3,160 patients with HER2-positive advanced breast cancer that had progressed after trastuzumab or taxane treatment. The trials covered eight treatment groups and seven HER2-targeted antibody-drug conjugates: T-DM1, ARX788, A166, SHR-A1811, RC48, DP303c and T-DXd. One trial enrolled only patients with liver metastasis and was used only in the visceral metastasis subgroup.\u003c\/p\u003e\n\u003ch3\u003eWhat does a hazard ratio of 0.18 mean?\u003c\/h3\u003e\n\u003cp\u003eA hazard ratio below 1 means the experimental treatment performed better than the comparison treatment for that outcome. In this analysis, T-DXd had a hazard ratio of 0.18 (95% CI 0.13–0.25) for progression-free survival compared with chemotherapy plus a tyrosine kinase inhibitor, the largest progression-free survival benefit among the seven conjugates. This was an indirect comparison, not a head-to-head trial.\u003c\/p\u003e\n\u003ch3\u003eDid these drugs help people live longer?\u003c\/h3\u003e\n\u003cp\u003eAll the conjugates in the overall survival analysis except ARX788, including SHR-A1811 and T-DXd, showed a statistically significant overall survival advantage over chemotherapy plus a tyrosine kinase inhibitor. SHR-A1811 had the strongest signal (hazard ratio 0.31, 95% CI 0.14–0.69). Survival data from several trials were not yet mature, so the authors call the survival ranking a hypothetical exploration rather than a definitive conclusion.\u003c\/p\u003e\n\u003ch3\u003eHow did side effects differ between the drugs?\u003c\/h3\u003e\n\u003cp\u003eSafety differed markedly. T-DXd had the highest odds of any-grade treatment-related side effects; its odds were 7.86 times higher than T-DM1 and 4.23 times higher than chemotherapy plus a tyrosine kinase inhibitor. T-DM1 had the lowest odds of severe (grade 3 or higher) side effects, significantly lower than SHR-A1811, ARX788, DP303c and chemotherapy plus a tyrosine kinase inhibitor.\u003c\/p\u003e\n\u003ch3\u003eWere the results different for hormone receptor-negative or organ-spread cancer?\u003c\/h3\u003e\n\u003cp\u003eIn patients with hormone receptor-negative, HER2-positive cancer, all treatment groups showed a significant progression-free survival advantage over chemotherapy plus a tyrosine kinase inhibitor, with T-DXd showing the largest (hazard ratio 0.17, 95% CI 0.11–0.27). In patients whose cancer had spread to internal organs, the conjugates also performed favourably. These subgroup results were consistent with the whole-population results.\u003c\/p\u003e\n\u003ch3\u003eHow reliable are these comparisons between individual drugs?\u003c\/h3\u003e\n\u003cp\u003eThese are indirect comparisons inferred through a common reference treatment, not head-to-head trials in the same patients. Each direct comparison rested on only one study, with no closed loops, so consistency between direct and indirect evidence could not be formally tested. Several trials were conference abstracts with incomplete reporting of missing data, and no trial was rated high risk of bias.\u003c\/p\u003e\n\u003ch3\u003eIf my HER2-positive advanced breast cancer has progressed after trastuzumab or a taxane, when should I get a second opinion on which antibody-drug conjugate to use?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is reasonable when the choice among antibody-drug conjugates is unclear. No head-to-head trials directly compare these drugs, so rankings come from an indirect network analysis of seven trials and 3,160 patients. T-DXd produced the largest progression-free survival benefit but had the highest odds of any-grade side effects, while T-DM1 had the lowest odds of severe side effects. Because efficacy and safety trade off differently, reviewing prior treatments, hormone receptor status, organ involvement and side-effect tolerance with another expert can help. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Liu F, Pan Y, Li J, Hu X, Yin G.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China; and Department of Pharmacy, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong, China\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Pharmacology, volume 17, article 1921830\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Received 28 June 2026; revised 11 September 2026; accepted 16 September 2026; published 28 September 2026. DOI: 10.3389\/fphar.2026.1921830. Open access under a Creative Commons Attribution License (CC BY).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSystematic review registration:\u003c\/strong\u003e PROSPERO, identifier CRD420251234345\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. It restructures the findings of one published network meta-analysis for a general audience. It does not replace advice from a qualified healthcare professional.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":48074019766428,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/fi\/products\/comparing-seven-antibody-drug-conjugates-for-previously-treated-her2-positive-advanced-breast-cancer-what-a-major-network-analysis-found","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}